Head‐to‐head trials of antibiotics for non‐cystic fibrosis bronchiectasis
References
Additional references
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012;186(7):657‐65.
Chang AB, Grimwood K, Mulholland EK, Torzillo PJ, Working Group on Indigenous Paediatric Respiratory Health. Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia 2002;177(4):200‐4. [PUBMED: 12175325]
Chang AB, Masel JP, Boyce NC, Wheaton G, Torzillo PJ. Non‐CF bronchiectasis: clinical and HRCT evaluation. Pediatric Pulmonology 2003;35(6):477‐83.
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes P, King PT, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Medical Journal of Australia 2010;193(6):356‐65.
Cole PJ. A new look at the pathogenesis and management of persistent bronchial sepsis: a Viscious Cycle hypothesis and its logical therapeutic connotations. In: Davies RJ editor(s). Strategies for the Management of Chronic Bronchial Sepsis. Oxford: Medicine Publishing Foundation, 1984.
Cole PJ. Inflammation: a two‐edged sword‐‐the model of bronchiectasis. European Journal of Respiratory Diseases. Supplement 1986;147:6–15.
Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In : Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Eastham KM, Fall AJ, Mitchell L, Spencer DA. The need to re‐define non‐cystic fibrosis bronchiectasis in childhood. Thorax 2004;59(4):324‐7.
Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. European Respiratory Journal 1996;9(8):1601‐4.
Evans DJ, Greenstone M. Long‐term antibiotics in the management of non‐CF bronchiectasis‐‐do they improve outcome?. Respiratory Medicine 2003;97(7):851‐8.
Felix Lambert M, Grundy S, Milan Stephen J, Armstrong R, Harrison H, Lynes D, et al. Dual antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012514]
Felix LM, Chalmers JD, Spencer S, Donovan T, Milan SJ, Mathioudakis AG. Continuous versus intermittent antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews In press.
Finch S, McDonnell MJ, Abo‐Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Annals of the American Thoracic Society 2015;12(11):1602‐11.
Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non‐cystic fibrosis bronchiectasis: a retrospective cross‐sectional analysis of CT diagnosed bronchiectatic patients. Respiratory Research 2012;13:21.
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 28 July 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Habesoglu MA, Ugurlu AO, Eyuboglu FO. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Annals of Thoracic Medicine 2011;6(3):131‐6.
Hansen MP, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, et al. Adverse events in patients taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD011825]
Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hill SL, Burnett D, Hewetson KA, Stockley RA. The response of patients with purulent bronchiectasis to antibiotics for four months. Quarterly Journal of Medicine 1988;66(250):163‐73.
Joish VN, Spilsbury‐Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non‐cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Applied Health Economics and Health Policy 2013;11(3):299‐304. [DOI: 10.1007/s40258‐013‐0027‐z]
Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non‐cystic fibrosis bronchiectasis. Chest 2012;141(4):1018‐24. [PUBMED: 21885727]
Kelly C, Evans David J, Chalmers James D, Crossingham I, Spencer S, Relph N, et al. Macrolide antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2016, issue 10. [DOI: 10.1002/14651858.CD012406; CD012406]
Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of non‐cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Annals of the American Thoracic Society 2015;12(12):1764‐70.
Martínez‐García MA, Soler‐Cataluña JJ, Perpiñá‐Tordera M, Román‐Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non‐cystic fibrosis bronchiectasis. Chest 2007;132(5):1565‐72.
Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross‐sectional study. PLoS Medicine 2016;13(5):e1002028.
Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non‐CF Guideline Group. British Thoracic Society guideline for non‐CF bronchiectasis. Thorax 2010;65(Suppl 1):i1–58.
Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population‐based cohort study. European Respiratory Journal 2016;47(1):186‐93. [DOI: 10.1183/13993003.01033‐2015]
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respiratory Medicine 2010;104(7):981‐5.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis‐associated hospitalizations in the United States, 1993‐2006. Chest 2010;138(4):944‐9.
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000‐2007. Chest 2012;142(2):432‐9.
Singleton R, Morris A, Reading G, Poll J, Holck P, Martinez P, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatric Pulmonology 2000;29(3):182‐7.
Spencer S, Felix LM, Milan SJ, Normansell R, Geominne PC, Chalmers JD. Oral versus inhaled antibiotics for non‐cystic fibrosis bronchiectasis. Cochrane Database of Systematic Reviews.
Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood 2005;90(7):737‐40. [PUBMED: 15871981]
Valery P, Morris P, Grimwood K, Torzillo P, Byrnes C, Masters IB, et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomized controlled trial. BMC Paediatrics 2012;12:122.
Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD010337.pub2]
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine 2005;12(4):205–9.
Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. European Respiratory Journal 1997;10(8):1754‐60.
Wilson R, Hansell DM, Loebinger MR. Definition and aetiology of non‐CF bronchiectasis. In: Blasi F, Miravitlles M editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013.
Wu Q, Shen W, Cheng H, Zhou X. Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology 2014;19(3):321–9.
